fashion -WSS

fashion

author：hotspot 2025-09-06 04:37:39 - browse：27812

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

focus

Wikipedia

WSS

Biden will tout long

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Brain MRIs reveal impact of 'toxic stress' on Black children

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

hotspot

fashion

entertainment

At least 13 dead in Texas as scorching temps continue

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How a small hospital in rural Puerto Rico survived Hurricane Maria

Apple is now the first public company to be valued at $3 trillion

AltruBio raises $225 million to develop ulcerative colitis drug

Supreme Court strikes down use of affirmative action

The creative science of coining drug names

Jerome Adams on the need for new antivirals for Covid

BIO to announce reorganization, senior leaders expected to depart

hotspot

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Why workplace violence is so common in health care

The creative science of coining drug names

Empower primary care with adequate payments and technology

Black vets could get higher VA benefits if race not used in lung test

focus

Wikipedia

focus

knowledge